## well-regarded brand with yearly revenue of about $750 million, but it

had a stagnant product line and yearly revenue growth of only 2%. (Two

of us, Duke and Will, are executives at Ajax.)

Prior to the purchase, the Ajax team and its investor partners had

reviewed Cordis’s product portfolio and identiﬁed signiﬁcant gaps

in multiple product ranges, such as products targeting circulatory

problems and others treating cardiac complaints. They would establish

an accelerator to develop products to ﬁll those gaps, and they

would be manufactured in Cordis’s plants and distributed through

Cordis’s existing sales and marketing channels. The development risks,

therefore, were conﬁned to the technical challenges.

Copyright © 2024 Harvard Business School Publishing. All rights reserved.

12

This document is authorized for use only by Matt O'Donnell (matthew.od11@gmail.com). Copying or posting is an infringement of copyright. Please contact customerservice@harvardbusiness.org or 800-988-0886 for additional copies.